Helen Of Troy Limited
$1.45B- Market cap
- $659.17M
- Debt
- +$810.54M
- Cash
- −$18.89M
Capital structure 45% equity / 55% debt · EV / Revenue 0.81x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: HELE stock price at discount vs ALNY $28.30 current versus $721.53 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ALNY's multiple
Implied fair value · at HELE's multiple
Snapshot Sep 8, 11:37 AM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: HELE FY 2026 (ended Feb 28, 2026) · ALNY FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 45% equity / 55% debt · EV / Revenue 0.81x
Capital structure 89% equity / 11% debt · EV / Revenue 10.07x · EV / EBITDA 62.69x
ALNY carries the larger enterprise value at $37.41B against $1.45B; HELE trades on the lower EV / Revenue multiple (0.81x vs 10.07x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
HELEN OF TROY LIMITED · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ALNYLAM PHARMACEUTICALS, INC. · implied price per share
At least 3 of the last 5 annual free-cash-flow observations must be positive.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
1.02x
5.22x
Net debt / EBITDA
Leverage against operating earnings
-1.10x
4.13x
Cash and equivalents
Liquid reserves on the balance sheet
$18.89M
$1.66B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEWELL BRANDS INC.
HELE vs NWL
IROBOT CORP
HELE vs IRBT
Spectrum Brands Holdings, Inc.
HELE vs SPB
GARMIN LTD
HELE vs GRMN
Moderna, Inc.
HELE vs MRNA
Sarepta Therapeutics, Inc.
HELE vs SRPT
VERTEX PHARMACEUTICALS INC / MA
HELE vs VRTX
BioNTech SE
HELE vs BNTX
ACADIA PHARMACEUTICALS INC
HELE vs ACAD
$810.54M
$4.12B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.